Catheter Precision, Inc.

Catheter Precision, Inc. develops and commercializes medical devices for cardiac electrophysiology and wound closure. Its current business is centered on two products: the VIVO System, which helps localize the origin of idiopathic ventricular arrhythmias, and LockeT, a suture retention device used to support wound healing. The company also has a history of technology development outside its current focus, including prior work on an excimer laser platform and more recently intellectual property related to cardiac-device interfacing. Catheter Precision sells through distributors and direct international relationships, with a meaningful portion of sales coming from outside the United States. The business remains early-stage and capital constrained, with recurring operating losses and a focus on product commercialization and regulatory expansion.

−2 323,3 %

92,3 %

−2 098,0 %

+95,0 %

0.10

0.08

— Catheter Precision, Inc.
%
Cardiac electrophysiology mapping60% 3D mapping and localization tools used by electrophysiologists to identify arrhythmia origin sites before procedures.
Surgical wound closure support30% Suture retention devices used to distribute tension and support wound healing during closure.
Software and service upgrades5% Optional software upgrades and related support services sold with the VIVO System.
International distribution and regulatory commercialization5% Commercial activity tied to distributor channels, CE Mark expansion, and market access work.

The company sells primarily to hospitals, electrophysiology labs, and clinicians treating cardiac arrhythmias, where...

  • Electrophysiology physicians and EP labsprimary

    Buy the VIVO System to help localize idiopathic ventricular arrhythmia origin sites before procedures.

  • Hospitals and surgical cliniciansprimary

    Buy LockeT for wound closure support and to help distribute suture tension over a larger area.

  • Independent medical device distributorssecondary

    Purchase and resell products in international markets, helping the company reach customers without a large direct sales force.

  • International healthcare providerssecondary

    Buy CE Mark-cleared products where local regulatory approval is required before commercialization.

Catheter Precision is headquartered in the United States, where it also records a majority of its sales...

  • •United States is the core revenue base and operating center
  • •Europe and the UK are early international commercialization markets
  • •CE Mark clearance expands access across the EU and EFTA countries
  • •Middle East distribution agreement supports non-U.S. growth for LockeT
  • •China patent issuance supports longer-term IP positioning

Catheter Precision's near-term strategy is to convert regulatory approvals into commercial adoption for both VIVO and...

01
Expand international commercializationshort-term

The company needs broader market access and distributor reach to scale sales without a large direct commercial infrastructure.

02
Support product adoption with clinical evidenceshort-term

Clinical data helps justify use, strengthen marketing claims, and potentially expand indications with regulators and clinicians.

03
Protect and reorganize intellectual propertymedium-term

IP ownership and patent coverage support long-term commercialization options and may create value outside the current operating plan.

Catheter Precision faces the risks typical of an early-stage medical device company: limited cash, recurring losses,...

high

Liquidity and going-concern pressure

The company has recurring operating losses and limited cash, so it may need additional financing to sustain commercialization and operations.

Scope
Corporate-wide
Materiality
high
high

Regulatory and market-access delays

Sales depend on FDA and CE Mark clearances and on local market access, so delays can directly reduce revenue opportunities.

Scope
VIVO System and LockeT international expansion
Materiality
high
medium

Commercial adoption risk

Clinicians and hospitals must adopt new devices based on workflow, evidence, and reimbursement considerations, which can slow uptake.

Scope
VIVO System and LockeT
Materiality
high
medium

Distributor concentration and execution risk

A meaningful part of international growth relies on independent distributors, which can limit control over pricing, promotion, and inventory.

Scope
Europe, UK, Middle East, other export markets
Materiality
medium
medium

Product liability and quality risk

Medical devices can face claims, recalls, or compliance issues if performance or manufacturing quality is inadequate.

Scope
All marketed products
Materiality
medium
Revenue recognition timing
Reported revenue and gross margin timing
Long-lived asset and intangible impairment
Operating results and balance sheet carrying values
Stock-based compensation
Operating loss and diluted share count
Income tax valuation allowance
Tax benefit/expense and equity

Stereotaxis, Inc.

STXS · Electromedical & Electrotherapeutic Apparatus

Cardio Diagnostics Holdings, Inc.

CDIO · In Vitro & In Vivo Diagnostic Substances

Adagio Medical Holdings, Inc.

ADGM · Surgical & Medical Instruments & Apparatus

VIVOS INC

RDGL · Surgical & Medical Instruments & Apparatus

AtriCure, Inc.

ATRC · Surgical & Medical Instruments & Apparatus

PRECISION BIOSCIENCES INC

DTIL · Biological Products, (No Diagnostic Substances)

: 28/04/2026